Rich Pharmaceuticals competitors

Rich Pharmaceuticals Competitors include Invectys, OSE Immunotherapeutics, X4 Pharmaceuticals and Rexahn Pharmaceuticals.
Add company...
Rich Pharmaceuticals
Rich Pharmaceuticals is a biopharmaceutical company that is focused on the development of its lead product, RP-323, for the treatment of acute myelogenous leukemia in refractory patients.
Invectys
Invectys is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers.
OSE Immunotherapeutics
OSE Immunotherapeutics (Nantes – ISIN : FR0012127173 ; Mnemo : OSE) was created in May 2016 through the merger of OSE Pharma, an immuno-oncology company developing specific immunotherapy activating T lymphocytes, and Effimune, a biotechnology company specializing in immune regulation with clinical applications in autoimmunity, transplantation and immuno-oncology.
X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
Rexahn Pharmaceuticals
Rexahn Pharmaceuticals develops treatments for cancer, central nervous system disorders, and other unmet medical needs in the United States.
Founding Date
Founding Date
N/A
Founding Date
2010
Founding Date
2012
Founding Date
2012
Founding Date
2001
Type
Type
Public
Type
Private
Type
Public
Type
Private
Type
Public
Tags
Locations
Locations
Beverly Hills, US HQ
Locations
Paris, FR HQ
Locations
Nantes, FR HQ
Paris, FR
Locations
Cambridge, US HQ
Locations
Rockville, US HQ
Employees
Employees
1
Employees
148% increase
Employees
2618% increase
Employees
303% increase
Employees
20
Valuation ($)
Valuation ($)
206.6 k
Valuation ($)
N/A
Valuation ($)
60.5 m
Valuation ($)
N/A
Valuation ($)
52.7 m

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 4.7m
Total funding raised
$ 10.3m
Total funding raised
$ 64.5m
Total funding raised
$ 5m
For sources of this data, please see the company profileDownload Excel

View company profiles

Invectys
HQ
Paris, FR
Employees
14↑ 8% increase

Invectys is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers.

View company
OSE Immunotherapeutics
HQ
Nantes, FR
Employees
26↑ 18% increase

OSE Immunotherapeutics (Nantes – ISIN : FR0012127173 ; Mnemo : OSE) was created in May 2016 through the merger of OSE Pharma, an immuno-oncology company developing specific immunotherapy activating T lymphocytes, and Effimune, a biotechnology company specializing in immune regulation with clinical applications in autoimmunity, transplantation and immuno-oncology.

View company
X4 Pharmaceuticals
HQ
Cambridge, US
Employees
30↑ 3% increase

X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.

View company
Rexahn Pharmaceuticals
HQ
Rockville, US
Employees
20

Rexahn Pharmaceuticals develops treatments for cancer, central nervous system disorders, and other unmet medical needs in the United States.

View company